Abstract: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
August 25, 2015
Assignees:
NC MEDICAL RESEARCH INC., ASKA PHARMACEUTICAL CO., LTD., MITSUI SUMITOMO INSURANCE CARE NETWORK CO., LTD.
Abstract: The invention relates to a polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, or a variant polypeptide or variant polynucleotide thereof, wherein the variant polypeptide has at least 73% sequence identity with the sequence set out in SEQ ID NO: 2 or the variant polynucleotide encodes a polypeptide that has at least 73% sequence identity with the sequence set out in SEQ ID NO: 2. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional polypeptide and functional equivalents of the gene or the amino acid sequence. The invention also relates to methods for using the polypeptide in industrial processes. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins.
Type:
Grant
Filed:
June 23, 2011
Date of Patent:
August 18, 2015
Assignee:
DSM IP ASSETS B.V.
Inventors:
Margot Elisabeth Francoise Schooneveld-Bergmans, Wilbert Herman Marie Heijne, Monica Diana Vlasie, Robbertus Antonius Damveld
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Type:
Grant
Filed:
December 12, 2013
Date of Patent:
August 18, 2015
Assignee:
Moderna Therapeutics, Inc.
Inventors:
Tirtha Chakraborty, Antonin de Fougerolles
Abstract: The present invention relates to a molecule capable of binding to adrenocorticotropic hormone (ACTH) with high affinity. The present invention also relates to use of the molecule for detection and/or purification of ACTH.
Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5?-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2?-deoxy-2?-fluoro modified nucleotide, a 2?-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2?-amino-modified nucleotide, 2?-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
June 30, 2015
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Ivanka Toudjarska, John M. Maraganore, Brian Bettencourt, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil Rajeev, Satyanarayana Kuchimanchi
Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.
Abstract: The present invention generally relates to droplets and/or emulsions, such as multiple emulsions. In some cases, the droplets and/or emulsions may be used in assays, and in certain embodiments, the droplet or emulsion may be hardened to form a gel. In some aspects, a heterogeneous assay can be performed using a gel. For example, a droplet may be hardened to form a gel, where the droplet contains a cell, DNA, or other suitable species. The gel may be exposed to a reactant, and the reactant may interact with the gel and/or with the cell, DNA, etc., in some fashion. For example, the reactant may diffuse through the gel, or the hardened particle may liquefy to form a liquid state, allowing the reactant to interact with the cell. As a specific example, DNA contained within a gel particle may be subjected to PCR (polymerase chain reaction) amplification, e.g., by using PCR primers able to bind to the gel as it forms. As the DNA is amplified using PCR, some of the DNA will be bound to the gel via the PCR primer.
Type:
Grant
Filed:
February 4, 2014
Date of Patent:
June 30, 2015
Assignee:
President and Fellows of Harvard College
Inventors:
Jeremy Agresti, Liang-Yin Chu, David A. Weitz, Jin-Woong Kim, Amy Rowat, Morten Sommer, Gautam Dantas, George Church
Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.
Type:
Grant
Filed:
July 8, 2014
Date of Patent:
June 23, 2015
Assignee:
Shire Human Genetic Therapies, Inc.
Inventors:
Braydon Charles Guild, Michael Heartlein, Frank DeRosa
Abstract: The present invention includes nucleic acid hybrid molecules capable of entering cells comprising at least one vivo-morpholino oligonucleotide (vivo-MO) comprising a guanidine-rich head conjugated to the 5? end, and at least one standard oligonucleotide comprising a gene-specific sequence and a standard oligonucleotide pairing sequence, wherein the standard oligonucleotide is bound to the vivo-morpholino oligonucleotide through base pairing to form a hybrid and wherein the vivo-morpholino oligonucleotide pairing sequence is complementary to the standard oligonucleotide pairing sequence.
Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.
Type:
Grant
Filed:
April 23, 2009
Date of Patent:
June 16, 2015
Assignee:
University of Saskatchewan
Inventors:
Scott Napper, Peter Hedlin, Philip Griebel, Lorne Babiuk, Neil Cashman, Avijit Chakrabartty, Andrew Potter
Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
Type:
Grant
Filed:
March 30, 2010
Date of Patent:
June 9, 2015
Assignee:
Icahn School of Medicine at Mount Sinai
Inventors:
Adolfo Garcia-Sastre, Anice C. Lowen, Peter Palese, John F. Steel
Abstract: A method of purifying a sample that includes a polynucleotide includes the steps of (i) providing a packed chromatographic column having negatively charged porous particles, (ii) equilibrating the column to the conditions to which the polynucleotide in the sample is to elute, (iii) contacting the sample with the packed chromatographic column such that the sample volume applied to the packed chromatographic column is less than or equal to the interparticle space of the negatively charged porous particles within the packed chromatographic column, (iv) eluting the polynucleotide from the packed chromatographic column, where the polynucleotide is in a purer state and in the conditions to which the packed chromatographic column was equilibrated.
Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
Abstract: The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.
Abstract: Precursor microRNA molecules that have been modified to prevent a protein involved in regulating developmental timing, oncogenesis, and/or neuronal growth from blocking processing of the precursor microRNA sequence to the mature microRNA are provided. Methods and kits for using the precursor microRNA molecules also are provided.
Type:
Application
Filed:
February 21, 2013
Publication date:
May 28, 2015
Applicant:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Mollie Katherine Meffert, Claudia R. Ruiz-Garzon, Yu-Wen A. Huang, Elizabeth C. H. Eyler
Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
Type:
Application
Filed:
January 30, 2015
Publication date:
May 28, 2015
Inventors:
Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel
Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
Type:
Application
Filed:
January 30, 2015
Publication date:
May 28, 2015
Inventors:
Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel
Abstract: The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.
Type:
Grant
Filed:
November 26, 2013
Date of Patent:
May 26, 2015
Assignee:
The Johns Hopkins University
Inventors:
Daniel Philip Judge, Peter Andersen, Lincoln Takura Shenje
Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.
Type:
Grant
Filed:
June 22, 2010
Date of Patent:
May 26, 2015
Assignee:
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH
Inventors:
Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
Abstract: The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.
Abstract: The invention concerns a system for modulating tissue physiology, for example, to prevent or reverse tissue damage caused by disease. The system utilizes vigilant cells that include stable vectors containing a gene switch/biosensor and a gene amplification system. The vectors allow expression of a transgene (such as a cardioprotective gene) in the vigilant cells to be regulated in response to a physiological signal, to be switched on or off, and to provide sufficient levels of the transgene product to achieve a desired result, e.g., prevention or reversal of myocardial cell damage. In addition to myocardial infarction, the vectors can be used to treat cells in a number of other disease states, including diabetes, cancer, stroke, and atherosclerosis. These approaches to stem cell-based gene therapy provide a novel strategy not only for treatment but for prevention of cell destruction.
Abstract: The present disclosure provides reagents that can be used to label synthetic oligonucleotides with rhodamine dyes or dye networks that contain rhodamine dyes.
Type:
Grant
Filed:
April 2, 2007
Date of Patent:
May 26, 2015
Assignee:
Applied Biosystems, LLC
Inventors:
Scott C. Benson, Ruiming N. Zou, Krishna G. Upadhya, Paul M. Kenney, Jonathan M. Cassel
Abstract: The present disclosure generally relates to dry solid matrices for the extraction, stabilization, and storage of nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the nucleic acids stored in the dry solid matrix are also described.
Type:
Grant
Filed:
December 20, 2012
Date of Patent:
May 26, 2015
Assignee:
General Electric Company
Inventors:
Brian Christopher Bales, Erik Leeming Kvam, Jason Louis Davis
Abstract: The invention relates to genes coding for TCP family transcription factors and having a biological role in the development of axillary buds and branch growth. Furthermore, the invention relates to the promoters of the transcription of said genes, to the genetic constructs containing same and to the uses thereof, including the use of agents that modulate the expression of these genes in order to modify plant architecture.
Type:
Grant
Filed:
November 27, 2009
Date of Patent:
May 26, 2015
Assignee:
Consejo Superior de Investigaciones Cientificas
Inventors:
Mar Martín Trillo, María Luisa Rodríguez Buey, Pilar Cubas Domínguez
Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
Type:
Grant
Filed:
March 26, 2012
Date of Patent:
May 26, 2015
Assignee:
NOVARTIS AG
Inventors:
Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
Abstract: DNA oligomers comprising sequences that are absent from the genome of one or more organisms of interest are used as reference markers (RMs). The RMs are added to biological samples to “tag” and subsequently identify the samples as authentic and to distinguish tagged samples from samples obtained without said markers, for example, in forensic, medical, legal and other applications.
Abstract: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.
Abstract: The present invention relates to pyrazolotriazolyl nucleoside analogues, oligonucleotide comprising them, and uses thereof. Further the invention relates to a method for reducing gene expression in a cell comprising transfecting the cell with such an oligonucleotide. It has been found, in accordance with the present invention, that certain pyrazolotriazolyl-based nucleoside analogues such as 8-[3?-(2-cyanoethyl)-(N,Ndiisopropyl)]-phosphoramidite-(2?-deoxy-5?-dimethoxytrity 1-13-D-ribofuranozyl)-4-{N-benzoylamino)-pyrazolo[1,5a]-1,3,5-triazine, can be incorporated into oligonucleotides, substituting natural purine nucleosides and imparting acid stability and nuclease stability to the oligonucleotide. Furthermore, oligonucleotides comprising one or more such nucleoside analogues are capable of hybridizing with oligonucleotides having complementary sequences thereto in which no such analogues are incorporated.
Type:
Application
Filed:
May 30, 2013
Publication date:
May 21, 2015
Inventors:
Jean-Christophe Truffert, Myriam Lefoix, Jean Hildesheim, Tirtsa Kleinman
Abstract: The present invention relates to novel nucleic acid molecules, called aptamers, that bind specifically to a small molecule fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.
Type:
Application
Filed:
September 8, 2014
Publication date:
May 21, 2015
Inventors:
Samie R. Jaffrey, Rita L. Strack, Grigory Filonov, Wenjiao Song
Abstract: Provided is a single-stranded nucleic acid aptamer specifically binding to Klebsiella pneumoniae, and a method for detecting Klebsiella pneumoniae by using the same. The aptamer of the present disclosure, and a method, a composition, a kit or a sensor of using the same may be used to specifically detect Klebsiella pneumoniae present in an aqueous environment, foods, and medical samples and also be applied in fields such as sanitary conditions of foods and medical diagnosis.
Type:
Application
Filed:
July 30, 2014
Publication date:
May 21, 2015
Applicant:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Byoung Chan KIM, Yeon Seok KIM, Jin Yang CHUNG, Jong Soo JURNG, Min Young SONG
Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.
Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.
Type:
Grant
Filed:
April 9, 2013
Date of Patent:
May 19, 2015
Assignee:
Centro de Ingenieria Genetica y Biotecnologia
Inventors:
Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
May 19, 2015
Assignee:
Centro de Ingenieria Genetica y Biotecnologia
Inventors:
Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
Abstract: Luminescent labels based on aromatic and heterocyclic compounds, including reactive intermediates used to synthesize these compounds, and methods of synthesizing and using these reporter compounds. These labels combine high photostabilities, large Stokes' shifts and contain a pyrimidinium moiety as a water-soluble group. These luminescent compounds relate generally to the following structure: The methods relate generally to the synthesis and/or use of reporter compounds for fluorescence lifetime or fluorescence polarization based applications.
Type:
Grant
Filed:
October 18, 2010
Date of Patent:
May 19, 2015
Assignee:
SETA BioMedicals, LLC
Inventors:
Leonid D. Patsenker, Inna G. Yermolenko, Iryna A. Fedyunyaeva, Yelena N. Obukhova, Olga N. Semenova, Ewald A. Terpetschnig
Abstract: A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer.
Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions.
Abstract: The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
May 19, 2015
Assignee:
DSM IP ASSETS, B.V.
Inventors:
Hendrik Wouter Wisselink, Antonius Jeroen Adriaan Van Maris, Jacobus Thomas Pronk, Paul Klaassen, Rene Marcel De Jong
Abstract: The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
May 19, 2015
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Sakari Kauppinen, Niels Abrahamsen, Robert Eldon Lanford
Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
May 19, 2015
Assignee:
California Institute of Technology
Inventors:
Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin, Irvin S. Y. Chen, Dong Sung An
Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.
Type:
Grant
Filed:
January 27, 2014
Date of Patent:
May 19, 2015
Assignee:
Universitat Ulm
Inventors:
Jörg Wiedenmann, Simone Kredel, Franz Oswald, Gerd Ulrich Nienhaus
Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed.
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
May 19, 2015
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
Inventors:
David B Weiner, Jean D Boyer, Michele Kutzler
Abstract: An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligonucleotide derivative are disclosed. wherein R3 is a first oligonucleotide; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide; R2 is a linker or a direct bond; Z1 is NR4, S, or O, and Z2 is NR4 or S, wherein R4 is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl. A method includes: synthesizing an oligonucleotide derivative comprising an amino or thiol group; and reacting a 3,4-dialkoxycyclobutene-1,2-dione with the oligonucleotide derivative to produce an oligonucleotide-squarate mono-conjugate.
Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.
Type:
Application
Filed:
June 14, 2013
Publication date:
May 14, 2015
Applicant:
N.V. Nutricia
Inventors:
Thomas Ludwig, Sylvie Huybers, Evan Abrahamse, Houkje Bouritius